Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia

Next Previous
Trial Profile

A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asenapine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational
  • Acronyms ADDRESS-97; Gemini-S26
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 10 Jul 2013 Planned end date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
  • 27 Jun 2013 New source identified and integrated (Clinical Trials Registry - India record: CTRI2012-02-002403).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top